Guru Raghavendra Valicherla

Dr. Guru Raghavendra Valicherla

Pharmaron (Exton) Lab Services LLC, Exton, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
KDKandarp M. Dave
Kandarp M. Dave
SASyed Anees Ahmed
Syed Anees Ahmed
Riyazuddin MohammedRiyazuddin Mohammed
Riyazuddin Mohammed
AGAnand P. Gupta
Anand P. Gupta
JGJiaur R. Gayen
Jiaur R. Gayen
Poor bioavailability of Docetaxel (DCT) arising due to its low aqueous solubility and permeability limits its clinical utility. The aim of the present study was to develop DCT loaded self-emulsified drug delivery systems (D-SEDDS) and evaluate its potential ability to improve the oral bioavailability and therapeutic efficacy of DCT. D-SEDDS were characterized for their in vitro antitumor activity, in situ single pass intestinal perfusion (SPIP), bioavailability, chylomicron flow blocking study and bio-distribution profile. The D-SEDDS were prepared using Capryol 90, Vitamin E TPGS, Gelucire 44/14 and Transcutol HP with a ratio of 32.7/29.4/8.3/29.6 using D-Optimal Mixture Design. The solubility of DCT was improved upto 50 mg/mL. The oral bioavailability of the D-SEDDS in rats (21.84 ± 3.12%) was increased by 3.19 fold than orally administered Taxotere (6.85 ± 1.82%). The enhanced bioavailability was probably due to increase in solubility and permeability. In SPIP, effective permeability of D-SEDDS was significantly higher than Taxotere. D-SEDDS showed 25 fold more in vitro cytotoxic activity compared to free DCT. Chylomicron flow blocking study and tissue distribution demonstrated the intestinal lymphatic transport of D-SEDDS and higher retention in tumor than Taxotere. The data suggests that D-SEDDS showed desired stability, enhanced oral bioavailability and in vitro antitumor efficacy.

24 January 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
KKKailas S. Khomane
Kailas S. Khomane
PMParth K. More
Parth K. More
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
Arvind BansalArvind Bansal
Arvind Bansal

1 February 2022 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
AHAthar Husain
Athar Husain
VMVishal Makadia
Vishal Makadia
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
MRMohammed Riyazuddin
Mohammed Riyazuddin
JGJiaur R. Gayen
Jiaur R. Gayen

1 October 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YPYogesh B. Pawar
Yogesh B. Pawar
HPHitesh Purohit
Hitesh Purohit
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
BMBhushan Munjal
Bhushan Munjal
SLShantanu V. Lale
Shantanu V. Lale
ABArvind Kumar Bansal
Arvind Kumar Bansal

1 April 2018 in Journal of Chromatography B
Verified
Journal Article
Closed access
HCHanumanth Cheruvu
Hanumanth Cheruvu
NYNavneet K. Yadav
Navneet K. Yadav
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
RARakesh K. Arya
Rakesh K. Arya
ZHZakir Hussain
Zakir Hussain
JGJiaur R. Gayen
Jiaur R. Gayen

1 December 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SASyed Anees Ahmed
Syed Anees Ahmed
SLShibani Lahiri
Shibani Lahiri
DMDivya Mohan
Divya Mohan
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
AGAnand P. Gupta
Anand P. Gupta
JGJiaur R. Gayen
Jiaur R. Gayen